131 Oyster Point Boulevard
South San Francisco, CA 94080
Full Time Employees: 109
|Dr. Tillman U. Gerngross||Co-Founder & Chairman||25k||N/A||1964|
|Dr. Arnon Rosenthal||Co-Founder, CEO & Director||637.87k||N/A||1955|
|Dr. Robert Paul M.D., Ph.D.||Chief Medical Officer||508.28k||N/A||1968|
|Dr. Robert S. King||Chief Devel. Officer||502.42k||N/A||1963|
|Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A.||Pres & COO||N/A||N/A||1971|
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.